Green Star Products (GSPI) 주식 개요는 미국에서 해조류 기반의 재생 가능한 연소 연료를 생산하는 회사입니다. 자세히 보기GSPI 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석최신 재무 보고서가 1년 이상 지났습니다.의미 있는 시가총액이 없습니다($919K)지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.모든 위험 점검 보기GSPI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0013해당 없음내재 할인율Est. Revenue$PastFuture-8k968k2016201920222025202620282031Revenue US$1.0Earnings US$0.09AdvancedSet Fair ValueView all narrativesGreen Star Products, Inc. 경쟁사Plastec TechnologiesSymbol: OTCPK:PLTY.FMarket cap: US$284.6kADM Tronics UnlimitedSymbol: OTCPK:ADMTMarket cap: US$5.3mTantech HoldingsSymbol: NasdaqCM:TANHMarket cap: US$5.6mGreystone LogisticsSymbol: OTCPK:GLGIMarket cap: US$5.7m가격 이력 및 성과Green Star Products 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.001352주 최고가US$0.002352주 최저가US$0.000005베타01개월 변동18.18%3개월 변동30.00%1년 변동44.44%3년 변동30.00%5년 변동-93.99%IPO 이후 변동-99.77%최근 뉴스 및 업데이트공시 • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0공시 • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.공시 • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.공시 • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.공시 • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.더 많은 업데이트 보기Recent updates공시 • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0공시 • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.공시 • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.공시 • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.공시 • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.주주 수익률GSPIUS ChemicalsUS 시장7D-27.8%0.1%1.2%1Y44.4%8.9%28.7%전체 주주 수익률 보기수익률 대 산업: GSPI은 지난 1년 동안 8.9%의 수익을 기록한 US Chemicals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: GSPI은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is GSPI's price volatile compared to industry and market?GSPI volatilityGSPI Average Weekly Movement45.7%Chemicals Industry Average Movement7.4%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%안정적인 주가: GSPI의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: GSPI의 주간 변동성은 지난 1년간 51%에서 46%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트1984n/aDennis Hopkinsgreenstarproductsinc.com는 미국에서 해조류 기반의 재생 가능한 연소 연료를 생산하는 회사입니다. 이 회사는 목재, 바이오디젤, 기타 공급원, 셀룰로오스 에탄올, 시아노박테리아 등 가정과 회사에서 에너지를 생산하는 데 사용할 수 있는 바이오 연료를 생산합니다. 이 회사는 이전에 B.A.T.더 보기Green Star Products, Inc. 기초 지표 요약Green Star Products의 순이익과 매출은 시가총액과 어떻게 비교됩니까?GSPI 기초 통계시가총액US$919.41k순이익 (TTM)US$968.10k매출 (TTM)n/a0.0x주가수익비율(P/E)0.0x주가매출비율(P/S)GSPI는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표GSPI 손익계산서 (TTM)매출US$0매출원가US$0총이익US$0기타 비용-US$968.10k순이익US$968.10k최근 보고된 실적Dec 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)0총이익률0.00%순이익률0.00%부채/자본 비율0.0%GSPI의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 19:26종가2026/05/22 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Green Star Products, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0
공시 • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.
공시 • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.
공시 • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.
공시 • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.
공시 • Mar 22Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.Green Star Products, Inc. has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 800,000,000 Price\Range: $0.0025 Discount Per Security: $0
공시 • Mar 12Green Star Products, Inc. Appoints Miss Kristy as New PresidentGreen Star Products, Inc. announced it now has a new president. Miss Kristy Hunt has been appointed President of Green Star Products, Inc.
공시 • Feb 27Green Star Products Announces Approving the Exclusive Licensing with Biotech ResearchMr. Joseph LaStella, President of Green Star Products, Inc. stated, “The Company has enough early votes to close the COVID-19 contract with BTR (Biotech Research, LLC).” The Company has already received 52% of shareholder’s votes, and over 90% have voted in favor of approving the exclusive licensing with Biotech Research. This approval ensures the final passage of the contract between Green Star Products and Biotech Research at the shareholders meeting. GSPI can now move ahead with this exclusive distribution agreement. For more details, please see press release dated December 21, 2020, titled: "Green Star Products: New Research Data Indicates 99.9% Effective Against The COVID-19 Virus.” The 2021 Special Shareholders Meeting is scheduled on March 3, 2021. Due to the COVID-19 pandemic, Green Star Products will not be holding an actual in-person stockholders meeting. In that web page can find a Letter to Stockholders with current information about Company operations, voting updates, and a Special Shareholder’s Discount Coupon Code for Viro Spectrum Shield (VSS) purchases and some information about this great anti-viral product. At the present time, Company is concentrating all its efforts on distribution of Viro Spectrum Shield, as it is of utmost importance that help save lives during this active pandemic. COVID-19 is mutating quickly and spreading throughout the world. VSS has been successfully tested against multiple viruses. It tested at 99.9% efficacy against the COVID-19 virus in vitro. Results verified by a United States Federally Accredited Laboratory prove that VSS is non-toxic and has shown Broad-Spectrum Antiviral capabilities. So many benefits to VSS, none more important than this formula can be used to combat the virus after infection as well as an all-natural preventative. Volunteers who were ill as a result of virus, many testing positive for the COVID-19 virus, used VSS and showed reversal of symptoms in 24-72 hours. See https://vssmt.net/for more information. VSS makes no claims, the evidence speaks for itself.
공시 • Dec 20Green Star Products, Inc. Announces New Research Data Indicates 99.9% Effective Against the COVID-19 VirusGreen Star Products, Inc. announced it received new data from a US Federally Accredited Laboratory stating, "In three replications at 3% and 10% concentration [of normal dosage of Viro Spectrum Shield], 100% of the cells were protected from signs of infection by the SARS-CoV-2 [COVID-19] virus, in vitro". Additionally, Viro Spectrum Shield (VSS) was specifically tested and found to be effective against the COVID-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Furthermore, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for COVID-19, have experienced significantly improved health and reduction or elimination of symptoms usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization. Viro Spectrum Shield is a proprietary blend of natural herbs and native plants. Presently, the blend is considered a dietary supplement.
공시 • Dec 13Green Star Products Signs Covid-19 Distribution ContractGreen Star Products, Inc. has signed a Distribution Contract with Biotech Research, LLC, to market/sell their Broad-Spectrum Antiviral Product, called Viro Spectrum Shield (VSS), in several South American countries. VSS has been tested by a US Federally Accredited Laboratory and has been successfully proven to inhibit SARS-CoV-2 (Covid-19) virus in vitro. VSS was specifically tested and found to be effective against the Covid-19 virus as well as the A/H1N1, A/H2N3, B/H2N3 flu viruses in vitro, which demonstrates its Broad-Spectrum Antiviral Capability. VSS was also tested and found to be non-toxic in vitro. Additionally, over the past nine months numerous infected volunteers with serious flu-like symptoms, including those who have tested positive for Covid-19, have experienced Significantly Improved Health and Reduction of Symptoms (or Elimination) usually within 24 to 48 hours or less with no side effects. None of these people needed hospitalization.
